Bryniarska-Kubiak N, Kubiak A, Basta-Kaim A. Mechanotransductive Receptor Piezo1 as a Promising Target in the Treatment of Neurological Diseases.
Curr Neuropharmacol 2023;
21:2030-2035. [PMID:
36173070 PMCID:
PMC10556366 DOI:
10.2174/1570159x20666220927103454]
[Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2022] [Revised: 08/16/2022] [Accepted: 08/28/2022] [Indexed: 11/22/2022] Open
Abstract
In recent years, increasing attention has been paid to the role of physical factors in biological processes. This direction was ultimately confirmed by the recent 2021 Nobel Prize in medicine and physiology awarded in ½ to Ardem Patapoutian for his discovery of Piezo1 and Piezo2 mechanosensitive receptors. Among them, Piezo2 is responsible for sensing touch, while Piezo1 is engaged in a variety of mechanotransduction events. Piezo1 is expressed in various central nervous system cells, while its expression may be affected in the course of various pathological conditions. Recently, thanks to the development of Piezo1 modulators (i.e. Yoda1, Jedi1/2 and Dooku2), it is possible to study the role of Piezo1 in the pathogenesis of various neurological diseases including ischemia, glioma, and age-related dementias. The results obtained in this field suggest that proper modulation of Piezo1 receptor might be beneficial in the course of various neurological diseases.
Collapse